Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$17.61 -1.0%	$15.59	$11.51 ▼ $21.50	$3.10B	0.52	55,714 shs	8,848 shs
IMVT Immunovant	$16.95 -7.5%	$16.23	$12.72 ▼ $34.47	$3.13B	0.63	1.14 million shs	4.51 million shs
IOVA Iovance Biotherapeutics	$3.13 -4.9%	$2.05	$1.64 ▼ $12.51	$1.10B	0.85	22.65 million shs	24.89 million shs
KYMR Kymera Therapeutics	$45.79 -0.1%	$42.50	$19.44 ▼ $53.27	$2.99B	2.18	772,263 shs	362,476 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	-0.96%	+0.11%	+13.76%	+20.53%	-6.03%
IMVT Immunovant	-7.48%	-5.36%	+7.62%	+15.15%	-39.33%
IOVA Iovance Biotherapeutics	-4.86%	+40.36%	+75.84%	-10.83%	-65.72%
KYMR Kymera Therapeutics	-0.13%	-0.84%	-1.46%	+37.67%	+6.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCM HUTCHMED	2.7515 of 5 stars	3.2	3.0	0.0	2.8	0.0	1.9
IMVT Immunovant	1.2878 of 5 stars	3.4	0.0	0.0	1.9	1.7	0.0
IOVA Iovance Biotherapeutics	4.6281 of 5 stars	4.2	1.0	4.2	2.8	4.2	0.6
KYMR Kymera Therapeutics	3.0182 of 5 stars	4.5	1.0	0.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.33	Hold	$23.50	33.45% Upside
IMVT Immunovant	2.82	Moderate Buy	$36.30	114.16% Upside
IOVA Iovance Biotherapeutics	2.33	Hold	$12.22	290.49% Upside
KYMR Kymera Therapeutics	3.05	Buy	$59.11	29.09% Upside

Current Analyst Ratings Breakdown

Latest IOVA, HCM, IMVT, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/15/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00

(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$630.20M	4.87	$0.28 per share	61.90	$4.43 per share	3.98
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
IOVA Iovance Biotherapeutics	$164.07M	6.37	N/A	N/A	$2.33 per share	1.34
KYMR Kymera Therapeutics	$58.89M	50.64	N/A	N/A	$12.90 per share	3.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$37.73M	N/A	0.00	12.06	N/A	N/A	N/A	N/A	8/7/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)

Latest IOVA, HCM, IMVT, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
8/5/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.08	2.83	2.70
IMVT Immunovant	N/A	11.16	11.16
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
KYMR Kymera Therapeutics	N/A	8.49	8.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
IMVT Immunovant	47.08%
IOVA Iovance Biotherapeutics	77.03%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
IMVT Immunovant	1.80%
IOVA Iovance Biotherapeutics	10.30%
KYMR Kymera Therapeutics	16.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable

IOVA, HCM, IMVT, and KYMR Headlines

Recent News About These Companies

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Buy" from Brokerages

July 22, 2025 | americanbankingnews.com

Jennison Associates LLC Sells 164,647 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 21, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Upgraded at The Goldman Sachs Group

July 18, 2025 | marketbeat.com

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

July 18, 2025 | zacks.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts

July 17, 2025 | marketbeat.com

Kymera Therapeutics Inc (KYMR) - Investing.com

July 11, 2025 | investing.com

Q3 EPS Estimate for Kymera Therapeutics Raised by Analyst

July 9, 2025 | marketbeat.com

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock

July 3, 2025 | investing.com

Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Morgan Stanley

July 3, 2025 | marketbeat.com

Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets

July 3, 2025 | investing.com

Insider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of Stock

July 2, 2025 | insidertrades.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bvf Partners L. P/Il Purchases 317,167 Shares

July 1, 2025 | marketbeat.com

Bros. Advisors Lp Baker Purchases 655,500 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

July 1, 2025 | insidertrades.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bros. Advisors Lp Baker Buys 655,500 Shares

June 30, 2025 | marketbeat.com

HC Wainwright Has Strong Forecast for KYMR FY2026 Earnings

June 30, 2025 | marketbeat.com

KYMR Q3 EPS Estimate Reduced by Brookline Capital Management

June 30, 2025 | marketbeat.com

Oppenheimer Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00

June 27, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Time to Buy?

June 27, 2025 | marketbeat.com

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

June 26, 2025 | globenewswire.com

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 4.1% Following Analyst Downgrade

June 26, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Price Target Lowered to $53.00 at Wells Fargo & Company

June 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

IOVA, HCM, IMVT, and KYMR Company Descriptions

HUTCHMED NASDAQ:HCM

$17.61 -0.17 (-0.96%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$17.74 +0.13 (+0.71%)

As of 07/25/2025 04:46 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant NASDAQ:IMVT

$16.95 -1.37 (-7.48%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$17.14 +0.20 (+1.15%)

As of 07/25/2025 06:46 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Iovance Biotherapeutics NASDAQ:IOVA

$3.13 -0.16 (-4.86%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$3.13 0.00 (0.00%)

As of 07/25/2025 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Kymera Therapeutics NASDAQ:KYMR

$45.79 -0.06 (-0.13%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$45.79 0.00 (0.00%)

As of 07/25/2025 04:11 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time